OncoNano Medicine has filed a notice of an exempt offering of securities to raise $15 Million in New Funding.

According to filings with the U.S. Securities and Exchange Commission, OncoNano Medicine is raising up to $15,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About OncoNano Medicine
OncoNano Medicine is a clinical-stage oncology company focused on transforming cancer therapeutics through its proprietary nanotechnology platform. Its ON-BOARD polymeric micelle platform is designed to use universal tumor targets to precisely deliver anti-tumor payloads to the tumor microenvironment. The company is developing a differentiated pipeline of novel therapies aimed at addressing significant challenges in cancer treatment. Notable recent developments include presenting new preclinical data at AACR 2026 demonstrating effective tumor delivery enabled by the ON-BOARD platform. OncoNano also announced a research collaboration with Gilead to apply its ON-BOARD delivery technology to a Gilead drug candidate.

To learn more, visit https://www.onconano.com/
LinkedIn: https://www.linkedin.com/company/onconano-medicine/

Contact:
Brett Giroir, Chief Executive Officer
https://www.linkedin.com/in/brett-giroir-512679204/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.